Oncology Central

RNA interference in the clinics: where are we standing now?


Over the last decade, the field of cancer therapy and the mode of action of approved cancer drugs have dramatically changed across the globe. The struggle against cancer in clinical trials shifted from the testing of cytotoxic ‘classical’ chemotherapeutic drugs toward agents with clearly defined molecular targets [1].

To view restricted content, please:

Leave A Comment